The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
A major push to sharpen the future of cancer treatment is underway
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
Highlights Mirvetuximab-based regimen promise
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The event showcased latest breakthroughs in minimally invasive surgery, organ-preservation strategies, and targeted therapies
Subscribe To Our Newsletter & Stay Updated
